Jangee

Drospirenone and ethinylestradiol, the active ingredients in Jangee, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age. GNH USA supplies Jangee as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jangee is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent unintended pregnancy. - Contraception: prevents pregnancy in women of childbearing potential. - Menstrual cycle regulation: helps achieve more regular menstrual periods. - Acne management: may improve acne associated with hormonal fluctuations.

Jangee may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing or tension‑type pain. - Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins, potentially life‑threatening. - Stroke or myocardial infarction: reduced blood flow to brain or heart. - Severe hypertension: markedly elevated blood pressure requiring medical attention.

Before prescribing Jangee, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess cardiovascular risk: review history of thromboembolic events, smoking, or hypertension. - Screen for liver disease: avoid use in active hepatic impairment. - Evaluate migraine status: contraindicated in women with migraine with aura. - Counsel on smoking: advise cessation, especially in women over 35 years. - Review medication history: consider interactions that may reduce efficacy. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Jangee can interact with several drug classes, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive efficacy. - Other estrogen‑containing products (e.g., hormone therapy): increase risk of estrogen‑related adverse events. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase hormone levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect mood‑related side effects. - St. John’s wort: may diminish contraceptive effectiveness.